Chlamydia infection Chlamydia infection, Doxycycline, Urethritis, Proctitis, Pharyngitis, Vaginitis, Sexually transmitted infection
Conditions
Interventions
Doxycycline 100 mg administered orally twice daily for three days.
Sponsors
Ando Naokatsu
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Adults aged 18 years or older at the time of consent acquisition. 2. Individuals in whom Chlamydia trachomatis has been detected in urine, pharyngeal, vaginal, or rectal specimens. 3. Individuals who have provided written consent to participate in the study.
Exclusion criteria
Exclusion criteria: 1. Individuals who are allergic to the treatment medication. 2. Individuals who are pregnant or breastfeeding. 3. Individuals whom the attending physician deems unsuitable for participation in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Treatment success rate at 28 days post-treatment (all sites) The treatment success is defined by a negative result on a nucleic acid amplification test after treatment. In cases of multiple site infections, the treatment is considered a failure if even one site remains positive. For each specific site, treatment success is confirmed by a negative result at the corresponding site. | — |
Secondary
| Measure | Time frame |
|---|---|
| Treatment success rate at 28 days post-treatment (by site) Treatment success rate at 14 days post-treatment (all sites, by site) Symptom resolution rate: the proportion of symptomatic individuals who experience symptom relief Incidence rate of adverse events | — |
Contacts
Public ContactAndo Naokatsu
National Center for Global Health and Medicine, Japan Institute for Health Security
Outcome results
None listed